Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from Imugene Limited ( (AU:IMU) ) is now available.
Imugene Limited has announced a proposed consolidation of its share capital, which will be voted on at an upcoming Extraordinary General Meeting. The consolidation will reduce the number of shares on issue from approximately 7.47 billion to about 219.6 million, without materially affecting the aggregate value of each shareholding or the company’s market capitalization. This move is expected to increase the market price per share, reflecting the reduced number of shares, and will also apply to all options currently on issue.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies designed to activate the immune system of cancer patients to treat and eradicate tumors. The company is engaged in creating a range of novel therapies, including an allogeneic cell therapy CAR T drug and multiple immunotherapy B-cell vaccine candidates, as well as an oncolytic virotherapy aimed at treating various cancers. Imugene’s mission is to transform cancer treatment and improve patient outcomes, supported by a team of international cancer experts.
Average Trading Volume: 22,481,270
Technical Sentiment Signal: Sell
Current Market Cap: A$171.7M
For an in-depth examination of IMU stock, go to TipRanks’ Stock Analysis page.